Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 037 IN DEXTROSE 5 AND SODIUM CHLORIDE 0 33 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 037 IN DEXTROSE 5 AND SODIUM CHLORIDE 0 33 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Potassium chloride provides potassium ions for maintenance of acid-base balance, isotonicity, and electrophysiological function; dextrose provides calories and may restore blood glucose levels; sodium chloride maintains fluid and electrolyte balance. The combination corrects hypokalemia and dehydration.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
Intravenous infusion at a rate of up to 10 mEq/h potassium chloride, with typical adult dose of 20-40 mEq potassium per 1000 mL of solution (e.g., 1 L of this preparation provides 5 mEq K+). Rate adjusted based on serum potassium and clinical status.
None Documented
None Documented
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
Potassium has a terminal elimination half-life of approximately 3-4 hours in healthy individuals, reflecting rapid renal clearance. However, redistribution and total body potassium turnover are slower (days) due to large intracellular stores. Clinical context: Half-life is prolonged in renal impairment or hypokalemia, and shortened in hyperkalemia.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Potassium is primarily excreted renally (90%) with minor fecal (10%) elimination. In this formulation, dextrose and sodium chloride are fully metabolized or excreted: dextrose undergoes cellular uptake and metabolism; sodium chloride is renally eliminated with sodium reabsorption and chloride as counterion.
Category C
Category A/B
Electrolyte
Electrolyte